Table 2 First (interim) PET/CT SUVmax (nodal and extra-nodal) and international prognostic index factors among first PET/CT treatment responder and non-responder groups
Initial responder (n = 16) | Initial non-responder (n = 17) | Test of significance | P value | |
|---|---|---|---|---|
1st PET/CT nodal SUVmax Median (min–max) | 1.8 (1.3–2.7) | 8.2 (1.4–25.1) | Z = 2.84 | 0.004* |
1st PET/CT extra-nodal SUVmax Median (min–max) | 1.70 (1.5–2.4) | 8.1 (3.6–34) | Z = 2.65 | 0.008* |
Age (Years) | FET | 0.044* | ||
< 60 years | 16 (100%) | 12 (70.6%) | ||
≥ 60 years | 0 (0%) | 5 (29.4%) | ||
Initial disease stage | χ2 = 5.54 | 0.019* | ||
I & II | 13 (81.2%) | 7 (41.2%) | ||
III & IV | 3 (18.8%) | 10 (58.8%) | ||
Serum LDH | χ2 = 6.85 | 0.009* | ||
Normal | 12 (75.0%) | 5 (29.4%) | ||
High | 4 (25.0%) | 12 (70.6%) | ||
Extra-nodal involvement | FET | 0.044* | ||
0–1 site | 16 (100%) | 12 (70.6%) | ||
More than 1 site | 0 (0%) | 5 (29.4%) | ||
Performance status | MC | 0.042* | ||
0 | 5 (31.2%) | 2 (11.8%) | ||
1 | 10 (62.5%) | 6 (35.3%) | ||
2 | 1 (6.2%) | 4 (23.5%) | ||
3 | 0 (0%) | 3 (17.6%) | ||
4 | 0 (0%) | 2 (11.8%) | ||
International risk category | χ2 = 9.93 | 0.002* | ||
Low risk | 16 (100%) | 9 (52.9%) | ||
High risk | 0 (0%) | 8 (47.1%) |